Psychedelics Today is the planetary leader in psychedelic education, media, and advocacy. Covering up-to-the-minute developments and diving deep into crucial topics bridging the scientific, academic, philosophical, societal, and cultural, Psychedelics Today is leading the discussion in this rapidly evolving ecosystem.
In this episode, David interviews Jim Gilligan: Interim CEO and Chief Scientific Officer of Tryp Therapeutics, a biotech company researching psychedelics for the treatment of eating disorders and nociplastic pain.